You are here: Home » Companies » News
Covid-19 impact: Analysts see over 20% decline in Q4 profit for GCPL
Business Standard

Lupin gets EIR from USFDA for its manufacturing plant in Nagpur

The company's shares surged 4.14% to Rs 820.40 after they received the inspection report (EIR) from the US drug regulator

Topics
USFDA | Lupin Pharma | Lupin

BS Web Team & Agencies 



lupin
The US health regulator issues an EIR to a company when an inspection is satisfactorily closed.

Pharma major has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its manufacturing plant in Nagpur on Monday.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Mon, April 13 2020. 11:54 IST

RECOMMENDED FOR YOU

.